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Abstract
Background: Insulinomas, which are rare tumors causing hyperinsulinemic hypoglycemia are usually sporadic but
may also occur in association with multiple endocrine neoplasia type 1 (MEN-1) syndrome an autosomal dominant
disorder caused by MEN1 gene mutations. MEN1 encodes a nuclear protein Menin, a tumor suppressor which acts
as an adapter and interacts with partner proteins involved in crucial activities like transcriptional regulation, cell
division, proliferation and genome stability.
This study reports on clinical findings and mutation screening in sporadic insulinoma patients.
Methods: Seventeen patients diagnosed with insulinoma were recruited along with 30 healthy volunteers who
acted as controls for the present study. The patients presented with symptoms of sweating, tremors, drowsiness,
palpitations, loss of consciousness, abnormal behavior, seizures and weight gain. Detailed clinical and family history
was collected from all the participants along with 5 ml of blood sample after taking informed consent.
Genomic DNA isolated from blood was subjected to MEN1 gene amplification followed by direct sequencing.
Nucleotide sequences obtained were compared with published MEN1 cDNA sequences. Prediction of functional
effects of novel changes was done using various bioinformatics algorithms.
Results: Molecular analysis revealed presence of three novel exonic mutations (M561K, Q192K and Q261Q),
two novel intronic variations c.445-44G→ A and c.913-42G→ C in introns two and six respectively and
three reported exon SNPs; H433H (rs540012), D418D (rs2071313), A541T (rs2959656) and one intronic
SNP (rs669976).
Conclusions: The study identified presence of novel pathogenic MEN1 mutations in sporadic cases of
insulinoma. The new mutations identified were in regions involved in defective binding of menin to
proteins implicated in genetic and epigenetic mechanisms. The outcome of the study extends the growing
list of MEN1 pathogenic mutations even in sporadic cases providing consequential insight into phenotypic
heterogeneity and in the expression of individual mutations.
Background
Insulinomas are neuroendocrine tumors of the pancreas
with an incidence of 0.4 % [1] and present clinically with
hypoglycemia [2]. They are usually benign solitary tu-
mours [3] but 5–12 % of the cases have distant meta-
stasis at diagnosis. Most of the insulinomas arise
sporadically, but 5–8 % may develop as part of the her-
editary multiple endocrine neoplasia type 1 (MEN1) syn-
drome [4, 5]. Insulinoma is the second most common
hormone secreting pancreatic neuroendocrine tumor in
MEN1. Other pancreatic neuroendocrine tumors are
gastriomas, glucagonomas, vasoactive intestinal polypep-
tidomas and their occurrence is 40–70 % in MEN1 pa-
tients [6]. Most of the insulinomas are small in size
(<2 cm) and over 99 % of them originate in the pan-
creas with rare cases derived from ectopic pancreatic
tissue [7]. Surgical removal is the main treatment and
the neurological sequelae of hypoglycemia after sur-
gery have been shown to revert [8].
MEN 1(OMIM 613733) located on chromosome
11q13.1, consists of ten exons spanning a region of >9 Kb
of genomic DNA [9] and encodes a 621 amino acid pro-
tein ‘menin’, a putative tumor suppressor gene associated
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with insulinoma [10]. Menin acts as an adapter and in-
teracts with partner proteins involved in crucial activ-
ities like transcriptional regulation, cell division,
proliferation and genome stability. Although located
predominantly in the nucleus, in the non dividing cells
it is found in the cytoplasm also [11]. We report here
the results of MEN 1 screening in 17 sporadic insuli-
noma patients along with their clinical findings.
Methods
The study protocol adhered to the tenets of the Declar-
ation of Helsinki and was approved by the Institutional
Ethics Committee of All India Institute of Medical Sci-
ences, New Delhi. Written informed consent was ob-
tained from each patient for publication of individual
clinical details.
A total of 17 patients diagnosed with insulinoma
from the department of Endocrinology and Metabolism
and 30 healthy volunteers as controls were recruited for
the present study. Insulinoma was suspected when a pa-
tient presented with recurrent hypoglycemia and a diag-
nosis of insulinoma was made when during spontaneous
or fast induced hypoglycemia plasma glucose was
<45 mg/dl, serum insulin was > 6 μU/ml and C peptide
was > 2.5 ng/ml [2]. After a biochemical diagnosis of hyper-
insulinomic hypoglycemia was confirmed, localization of
insulinoma was done by various imaging modalities like
multiphasic CT, MRI, arterial calcium stimulation and ven-
ous sampling, endoscopic ultrasound and intraoperative
ultrasound. After localization, the tumor was removed and
location and size of the tumor intraoperatively was noted.
From all the participants detailed family history was noted
and peripheral blood drawn in EDTA vials for DNA
extraction.
Mutation analysis
Genomic DNA was isolated from peripheral blood leu-
kocytes using standard protocol and subjected to PCR
amplification of all the MEN1 coding exons using 80–
100 ng DNA, 1.25 mM MgCl2, 0.25 mM of each of the
dNTPs (Invitrogen, Carlsbad, CA, USA), 20pM of each
primer and 0.5 units of Taq Polymerase (Invitrogen,
Carlsbad, CA, USA) in a 25 ul volume mixture using
thermocycler ABI 9700 (Applied Biosystems, Foster City,
CA).
All the amplified products were purified using Qiagen
kits (Qiagen, GmbH, Hilden, Germany) and were then
sequenced using ABI-3100 Genetic Analyzer (ABI).
Nucleotide sequences were compared with the pub-
lished cDNA sequences of MEN1 gene (GenBank acces-
sion number ENST00000312049). Prediction of functional
effects of the novel variations was done using algorithms
Mutation Taster, SIFT and PROVEAN.
Results
Out of 17 patients, ten were males and seven were fe-
males. Main presenting symptoms were recurrent
hypoglycemia, seizures, confusion and excessive weight
gain. History of sweating, tremors and drowsiness was
present in all (100 %) the patients, 13 (76.47 %) patients
had palpitations, weakness and weight gain whereas only
12 (70.59 %) patients had loss of consciousness, abnor-
mal behavior and seizures. Out of all, 15 (88.24 %) pa-
tients had been to the neurologist and/or psychiatrist for
treatment before a diagnosis of insulinoma was made.
The mean age at presentation was 35 ± 13 years. The
mean duration of symptoms was 3.56 years (range 1 to
15 years) before diagnosis of insulinoma was established.
The mean levels of insulin was 17.36 μU/ml (range 6.5
to 153), C peptide was 5.05 ng/ml (range 0.88 to 11.90)
and mean plasma glucose of 32.86 mg/dl (range 18 to
45 mg/dl).
Other components of MEN1 syndrome were ruled out
by taking history of symptoms, noting sign and labora-
tory tests. Clinical features of anterior pituitary tumors
asked for were irregular periods, galactorrhoea, and in-
fertility in females, erectile dysfunction in males, head-
ache, visual impairment, central obesity and proximal
muscle weakness in both. Signs looked for were presence
of violaceous stria, buffalo hump, acral enlargement,
prognathism, frontal bossing, thyroid enlargement. Clin-
ical features of hyperparathyroididm asked for were
bone pain, history of fractures, renal stones and abdom-
inal pain. Laboratory testes performed to rule out pituit-
ary or parathyroid tumors were serum fasting prolactin,
ACTH, cortisol, growth hormone and insulin like growth
factor1, T4, TSH, intact PTH, calcium and phosphorus.
These symptoms/signs were absent and tests were normal
in all the patients.
There was no history of consanguinity in any of the
families. Only one patient (6 %) had malignant insuli-
noma and rests were benign. Insulinomas were found lo-
cated in different parts of the pancreas and the sites of
the primary tumors were junction of neck and body in
one patient (6 %), uncinate process in two patients
(12 %) and in seven patients each (41 %) it was located
in head and tail of the pancreas (Table 1). All the pa-
tients (100 %) underwent surgery as curative procedure.
Only one patient underwent resection twice because of
recurrence of the tumor at different times.
MEN1 screening revealed presence of novel changes
which include two non-synonymous missense muta-
tions; M561K in which a nucleotide changes from T
to A resulted in amino acid methionine being re-
placed by lysine at codon 561 in exon ten and Q192K
resulting due to sequence variation C > A leading to
amino acid change from Glutamine to Lysine at
codon 192.
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Table 1 Tumor characteristics and MEN1variations in insulinoma patients
ID. Age/Sex Tumour characteristics MEN1 variations found
Location Size Nature
M1 35/M 3 2.0 a2.0 cm B Q260Ra
A541T (rs2959656)d
H433H (rs 540012)d
M2 38/M 3 4.8a5.9 cm M H433H (rs 540012)d
M3 23/M 3 1.0a0.8 cm B H433H (rs 540012)d
D418D (rs2071313)d
M4 34/M 3 0.8a0.9 cm B H433H (rs 540012)d
A541T (rs2959656)d
M5 42/M 3 1.0 x 0.8 cm B H433H (rs 540012)d
D418D (rs2071313)d








Intronic rs 669976 e
M8 50/F 2 3.0a2.0 cm B H433H (rs 540012)d
D418D (rs2071313)d
A541T (rs2959656)d
M9 25/M 4 4.0a5.0 cm B H433H (rs 540012)d
A541T (rs2959656)d
M10 29/F 4 1.0a0.5 cm B H433H (rs 540012)d
A541T (rs2959656)d
M11 16/M 3 1.0 x 1.0 cm B H433H (rs 540012)d
A541T (rs2959656)d
M12 18/F 3 2.0 x 1.0 cm B H433H (rs 540012)d
Intronic rs 669976 e
A541T (rs2959656)d
M13 17/M 4. 2.0 a2.0 cm B Q192K a
H433H (rs 540012)d




M15. 46/M 4 1.0a1.0 cm B H433H (rs 540012)d
A541T (rs2959656)d
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A novel synonymous mutation (Q261Q) resulting in a
nucleotide change from G to A at codon 261 was also
identified with no change in the amino acid glutamine
(Q).
Three reported exonic polymorphisms were identified:
H433H (rs540012) in all patients and controls, D418D
(rs2071313) in 8 (47 %) patients; none of the controls
and A541T (rs2959656) in 11 (65 %) patients and in all
the controls.
A reported intronic polymorphism rs669976 was iden-
tified in two (12 %) patients and was absent in all the
controls. Two novel intronic variations c.445-44G→A
in intron 2 and c.913-42G→C located in intron six
were also identified (Table 1).
Assessment for pathogenicity using MutationTaster,
PROVEAN and SIFT predicted all the novel exonic mu-
tations and novel intronic variation (c.913-42G→C) to
be deleterious and disease causing alterations.
To confirm the findings from genetic screening and
bioinformatics analysis, 30 healthy controls were screened
to check for the presence of the novel variations. The
changes were not identified in any of them eliminating
their possibility of being polymorphisms.
Discussion
In the present study we report clinical and genetic find-
ings of 17 patients diagnosed with insulinoma. Clinical
presentations of insulinomas are diverse and heteroge-
neous. Hypoglycaemia results in various neuroglycopenic
and adrenergic symptoms. Neuroglycopenic symptoms in-
clude many psychiatric and neurological manifestations
like behavioural changes, confusion, agitation, blurred vi-
sion and finally seizures [12, 13]. All the 17 patients
(100 %) in the present report had hypoglycemia with
neurological manifestations like confusion and seizures.
Pancreatic islet cell tumors can be the first manifest-
ation in 15 % of all the MEN1 cases [14]. Insulinoma
may arise either due to loss of heterozygosity (LOH) of
the chromosome region 11q13 or due to presence of
various mutations in the MEN-1 gene [15, 16] in accord-
ance with the Knudson’s hypothesis on cancer [17]. Most
of the insulinomas are benign and are found located any-
where in the pancreas and surgical removal is the first line
of treatment. Malignant insulinomas are comparatively
rare and are found in around 5–12 % of reported insuli-
noma cases [18] . Without curative treatment MEN1 insu-
linomas are found to be associated with earlier mortality
in the patients[19]
In the present study, only one patient (6 %, n = 17;
38 years, male) had malignant insulinoma. The size of
the tumor was 4.8*5.9 cm located in the head of the pan-
creas with multiple metastases in the liver. He was oper-
ated and died within two years of diagnosis. No MEN1
mutation was identified in this patient indicating pos-
sible presence of other important genetic events like in-
volvement of other unidentified gene/s, chromosomal
instability resulting in insulinoma development, and
probably the presence of phenocopies [15, 20]. Rest of
the patients had benign tumors for which they got oper-
ated and are alive without recurrence of the disease.
The MEN1 gene encodes ‘menin’ which is a nuclear
scaffold protein that regulates gene transcription by al-
tering chromatin remodeling. It functions as a tumor
suppressor gene and interacts with several transcription
factors like JUND, NFKB, SMAD3 etc. [19]. MEN1 gene
mutations are well characterized with approximately
1330 mutations scattered throughout the entire gene
comprises of mostly frameshift deletions or insertions,
followed by nonsense, missense, splice-site mutations
and either part or complete gene deletions [21].
Frameshift and nonsense mutations result in truncated
and most probably inactive menin protein whereas splice
site mutations result in incorrect splicing of the mRNA
which leads to either exon skipping or addition of extra
region to the final product.
Missense mutations of MEN1 are important as they
result in change of crucial amino acids necessary for
binding or interacting with various other molecules and
proteins. This may further affect the functional activity
of the menin protein or its expression levels. Studies
have shown single amino acid change in the genes in-
volved in oncogenic disorders to result in enhanced
Table 1 Tumor characteristics and MEN1variations in insulinoma patients (Continued)
M16. 30/M 4 1.0a1.0 cm B Intronic c.913-42G→ Cc
H433H (rs 540012)d
D418D (rs2071313)d
M17 41/F 4 0.85a0.65 cm B Intronic c.445-44G→ Ac
H433H (rs 540012)d
A541T (rs2959656)d
Legend: M male, F female, B benign, M malignant, 1-junction of neck and body of the pancreas, 2-uncinate process of the pancreas, 3-head of the pancreas, 4-tail
of the pancreas. a - novel non synonymous exonic mutations, b- novel synonymous exonic mutation, c novel intronic variations, d -reported exonic polymorphisms,
e- reported intronic polymorphisms
Jyotsna et al. BMC Endocrine Disorders  (2015) 15:44 Page 4 of 6
proteolytic degradation leading to reduced stability and
loss of function of the mutant protein which is a com-
mon mechanism for inactivating tumor suppressor gene
products [22, 12].
Menin has three nuclear localization signals (NLS)
near the C terminus of the protein and the novel
M561K mutation identified lies within the second NLS
domain. This region of menin is postulated to have a
role in interaction with transcription factors like Smad3
and CHES1 and cell cycle control proteins like ASK
[15]. The patient with this mutation was a 65 years old
woman who presented with episodes of fasting and post
prandial hypoglycemia, frequency of which had increased
over the last 8 years. The patient had one benign tumor
measuring 1.5*1.2 cm located in the uncinate process of
pancreas.
In the present study a missense mutation (Q192K) was
identified at amino acid 192 in a 17-year-old male pa-
tient having symptoms of tremors, drowsiness, headache,
generalized tonic clonic seizures for 13 months. A
2*2 cm insulinoma was localized in the pancreatic tail
which was surgically removed. A previous study [13] has
reported a nonsense mutation (Q192X) at this position.
This region of menin interacts with proteins JunD re-
sponsible for transcription regulation, HDAC for epigen-
etic regulation, NMMHC II-A having a role in cell
division and NM23A which plays a role in cell cycle
control [15].
Apart from this, a silent mutation Q261Q identified
had no change in the amino acid but the variation G > A
is at the last nucleotide of exon 4/intron four boundary
forming a part of conserved sequences required for spli-
cing. This change might be resulting in incorrect splicing
leading to an abnormal protein. Pathogenicity of the
alteration was evaluated by Mutation Taster software
which predicted the change to be disease causing (prob-
ability =1; indicating high security of the prediction).
An accurate splicing mechanism is required for removal
of introns and forming the mature RNA which normally
takes place by a large spliceosome complex that includes
small nuclear ribonucleoprotein particles (snRNP) and a
number of other proteins. This spliceosomal complex as-
sembly requires the presence of conserved recognition se-
quences in the pre-mRNA for silencers, enhancers etc.
These sequences may be present in the exons as well as
introns. Alterations in any of these conserved sequences
or elements may severely impair pre-mRNA splicing and
gene expression. Various nonsense, missense and even si-
lent mutations can inactivate genes by impairing the effi-
ciency of splicing machinery thereby resulting in diseased
phenotype [23].
Of the known polymorphisms identified in the present
study, D418D (rs2071313) was the only one absent in
the controls whereas H433H (rs540012) and A541T
(rs2959656) were present in all the controls indicating
that these polymorphisms may not be associated with in-
creased tumor risk. However, the status of the poly-
morphism A541T is controversial as several studies
report this to be a mutation associated with parathy-
roid tumors whereas others have reported this to be a
non-pathogenic polymorphism present in pancreatic
tumors [24–26].
Several reports also document intronic variations af-
fecting mRNA splicing and leading to mild disease phe-
notypes with low penetrance [27, 28]. Two novel
intronic variations c.445-44G→A and c.913-42G→ C
identified in the present study were absent in the control
individuals suggesting their probable association with
the disease. However, this needs further validation through
more mutational and functional studies.
Conclusions
In conclusion, we report the clinical and genetic findings
in 17 patients with the rare condition of sporadic insuli-
nomas. The significance of this study is the identification
of three novel exonic and two novel intronic variations.
The outcome of the study considerably extends the
growing list of pathogenic MEN1 mutations providing a
consequential insight into phenotypic heterogeneity and
in the expression of individual mutations. The new mu-
tations identified seem to confer a role in defective bind-
ing of the menin protein to specific molecules involved
in a variety of genetic and epigenetic mechanisms
thereby resulting in disease pathology.
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